SRM-IV眩晕诊疗系统联合天麻素注射液治疗良性阵发性位置性眩晕的临床研究

The clinical research on treating BPPV by SRM-IV vertigo diagnose and treatment system plus the Tianmasu injection

目的:探讨SRM-IV眩晕诊疗系统联合天麻素注射液治疗良性阵发性位置性眩晕(Benign Paroxysmal Positional Vertigo,BPPV)的临床疗效。方法:将315例原发性BPPV患者随机分四组:手法诊断复位联合天麻素组(77例);手法诊断复位联合安慰剂组(84例);SRM-IV诊断复位联合天麻素组(79例);SRM-IV诊断复位联合安慰剂组(75例)。治疗两周时评价四组生活质量及临床疗效,随访6个月并记录眩晕复发情况。结果:四组患者临床疗效比较,差异无统计学意义(P>0.05);四组治疗后情感、功能、躯体评分明显降低(P<0.05),SRM-IV诊断复位联合天麻素组较其他组降低程度更明显(P<0.05);随访6个月后,SRM-IV诊断复位联合天麻素组、SRM-IV诊断复位联合安慰剂组患者复发率明显低于其他两组(P<0.05),SRM-IV诊断复位联合天麻素组与SRM-IV诊断复位联合安慰剂组比较,差异无统计学意义(P>0.05)。结论:SRM-IV眩晕诊疗系统联合天麻素注射液治疗良性阵发性位置性眩晕,疗效确切,可提高BPPV患者生活质量,降低BPPV的复发率,为BPPV患者规范化治疗提供了理论依据。

Objective: To discuss the clinical effect of SRM-IV vertigo diagnose and treatment system plus the Tianmasu injection (天麻素注射液) on BPPV. Methods: 315 patients with primary BPPV were randomly divided into the diagnosis and reset by manipulation plus the Tianmasu injection group (77 cases), diagnosis and reset by manipulation plus placebo group (84 cases), SRM-IV diagnosis and reset plus the Tianmasu injection group (79 cases), SRM-IV diagnosis and reset plus placebo group (75 cases). Quality of life and clinical efficacy were evaluated at 2 weeks, the recurrent cases of vertigo were recorded after 6 months of follow-up. Results: There were no statistically significant differences in clinical efficacy between the four groups (P>0.05). The scores of emotional, functional and somatic in the four groups were significantly decreased after treatment (P<0.05), the reduction degree of SRM-IV diagnosis and reset plus the Tianmasu injection group was more obvious than other groups (P<0.05). After 6 months of follow-up, the rate of recurrence in the SRMIV diagnosis and reset plus the Tianmasu injection group and SRM-IV diagnosis and reset plus placebo group were significantly lower than other 2 groups(P<0.05), and there was no statistically significant difference between SRM-IV diagnosis and reset plus the Tianmasu injection group and SRM-IV diagnosis and reset plus placebo group(P>0.05). Conclusion: SRM-IV vertigo diagnose and treatment system plus the Tianmasu injection on BPPV was effective, which can improve the quality of life of BPPV patients and reduce the recurrence rate of BPPV, can also provide theoretical basis for the standardized treatment of BPPV patients.